1.Low-dose systemic retinoids in preventing subsequent non-melanoma skin cancers (NMSC) in patients with history of NMSC: A systematic review.
Jolene Kristine G. GATMAITAN-DUMLAO ; Francesca Mari P. SUMILANG ; Cynthia P. CIRIACO-TAN
Philippine Journal of Internal Medicine 2017;55(2):1-7
<p style="text-align: justify;">BACKGROUND: Non-melanoma skin cancers (NMSC) consists of basal-cell carcinomas (BCC) and squamous-cell carcinomas (SCC).Certain populations are predisposed to develop NMSC, including patients with previous history of NMSC.Systemic retinoids have shown promising results in chemoprevention of recurrence of NMSC in other high-risk populations (xeroderma pigmentosum and renal-transplant patients).We assessed the efficacy and safety of low-dose systemic retinoids compared with placebo, as a chemopreventive agent for NMSC in patients with previous NMSC.
METHODOLOGY: Electronic databases were systematically searched for this study. Participants in the studies selected must have had a biopsy-proven NMSC, over 18 years of age, with no exclusion of other demographic characteristics. All types of systemic retinoids were included with no restriction on dosage. Two authors independently performed standardized eligibility assessment and data-extraction.Differences in opinion were resolved by consensus with the third author. Statistical analysis was done using the Review Manager 5 software.
RESULTS: Eleven full-text studies were assessed for eligibility out of 178 studies found. Five studies were excluded because of the different population, while the two articles used topical retinoids. Four articles were included. The interventions were 10.0 mg isotretinoin, 25,000IU retinol and 25.0 mg acitretin,compared with placebo. Meta-analysis produced RR of 0.94 (95% CI, 0.89-1.00), with moderate heterogeneity (34%) due to the difference in interventions used. There are significantly more adverse events in the retinoids group, especially in the incidence of mucocutaneous adverse events, and deranged lipid profile and liver enzymes.
CONCLUSION: There is insufficient evidence to support the use of low-dose systemic retinoids as chemoprevention for patients with previous NMSC. Furthermore, adverse events may limit their use. Topical preparations with less side-effects may be investigated.p>
Human
;
Male
;
Female
;
Aged
;
Middle Aged
;
Adult
;
Vitamin A
;
Acitretin
;
Xeroderma Pigmentosum
;
Isotretinoin
;
Incidence
;
Kidney Transplantation
;
Carcinoma, Basal Cell
;
Carcinoma, Squamous Cell
;
Chemoprevention
;
Biopsy
;
Lipids
;
Liver
2.Multiple eruptive myxoid dermatofibroma in a male with chronic hepatitis B infection.
Francesca Mari P SUMILANG ; Claudine Y SILVA ; Eileen Liesl A CUBILLAN ; Georgina C PASTORFIDE
Acta Medica Philippina 2017;51(4):334-336
<p style="text-align: justify;">We report the first published case of multiple eruptive myxoid dermatofibroma (MEMDF) in a male with chronic hepatitis B infection presenting with eruptive lesions showing marked deposits of dermal mucin. Alcian blue and immunohistochemistry confirmed the diagnosis of myxoid dermatofibroma. Further work-up showed asymptomatic chronic hepatitis B infection without cirrhosis.This case highlights an extremely rare histologic variant and the importance of screening for altered immunity in patients with eruptive dermatofibromas.p>
Human
;
Female
;
Middle Aged
;
Histiocytoma, Benign Fibrous
;
Mucins
;
Alcian Blue
;
Hepatitis B, Chronic
;
Immunohistochemistry
;
Muc1 Protein, Human
;
Mucin-1
;
Liver Cirrhosis
;
Exanthema